[Form 4] MacroGenics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MacroGenics insider award: Senior Vice President and General Counsel Jeffrey Stuart Peters received an employee stock option grant for 30,000 shares on 08/15/2025. The option has an exercise price of $1.58, vests 25% after one year with the remaining 75% vesting in 12 substantially equal quarterly installments, and expires on 08/15/2035. Following the reported transaction Mr. Peters beneficially owns 30,000 common shares subject to the option on a direct basis. The Form 4 was signed by an attorney-in-fact on 08/19/2025.

Positive

• 30,000 option grant disclosed with clear terms and vesting schedule
• Exercise price stated at $1.58 and expiration date provided (08/15/2035)
• Vesting schedule detailed: 25% after one year then 12 quarterly installments
• Direct beneficial ownership after the transaction is explicitly reported (30,000)

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: An executive equity grant with multi-year vesting aligns leadership incentives with long-term shareholder value.

The filing documents a standard employee stock option award to the company's Senior Vice President and General Counsel. The vesting schedule—25% after one year then quarterly over three years—creates a multi-year retention mechanism. The expiration date extends ten years from grant, which is typical for option grants. The disclosure is routine, showing direct beneficial ownership of 30,000 underlying shares after grant. No additional corporate actions or departures are reported in this Form 4.

Executive Compensation Analyst

TL;DR: Option grant size and schedule are clearly disclosed; structure is consistent with common executive compensation practices.

The Form 4 specifies an employee stock option for 30,000 shares at a $1.58 exercise price with explicit vesting terms and a 10-year contractual life. The filing provides the necessary mechanics and ownership post-grant, enabling assessment of the award's timeline and potential future vesting events. The report is concise and contains no other compensatory details or cash transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peters Jeffrey Stuart

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior VP and General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.58	08/15/2025		A		30,000		(1)	08/15/2035	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. 25% of the options will vest and become exercisable one year after the grant date and the remaining 75% will vest in 12 substantially equal quarterly installments thereafter.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jeffrey Stuart Peters disclose on his Form 4 for MGNX?

The Form 4 discloses an employee stock option grant of 30,000 shares with an exercise price of $1.58, granted on 08/15/2025.

What are the vesting terms of the option grant reported by MGNX insider?

The option vests 25% one year after the grant date and the remaining 75% in 12 substantially equal quarterly installments thereafter.

When does the reported option expire according to the Form 4?

The option expires on 08/15/2035, ten years after the grant date.

Does the Form 4 show how many shares Mr. Peters owns after the grant?

Yes. The filing shows Mr. Peters beneficially owns 30,000 underlying shares on a direct basis following the reported transaction.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by Beth A. Smith, Attorney-in-fact on 08/19/2025.